Iovance Biotherapeutics, Inc. stock faces challenges with disappointing Q1 earnings and competition. Click for why potential ...

Analysts are intrested in these 5 stocks: ( ($O) ), ( ($GTLB) ), ( ($DASH) ), ( ($IOVA) ) and ( ($SENS) ). Here is a breakdown of their recent ...

SAN CARLOS, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor ...

Iovance Biotherapeutics’ Amtagvi study data shows 49 per cent response rate for commercialisation: San Carlos, California Thursday, July 17, 2025, 12:00 Hrs [IST] Iovance Biothe ...

Iovance Biotherapeutics has proven to be an innovative biotech. Over the past two years, Iovance Biotherapeutics (NASDAQ: ...

Iovance Biotherapeutics has hired Corleen Roche as the biotechnology company's new chief financial officer, effective Aug. 6. Iovance on Tuesday said Roche, 59 years old, most recently served as ...

Line or Earlier Patients SAN CARLOS, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and ...

S hares of Iovance Biotherapeutics (NASDAQ: IOVA) have collapsed by about 47% from the peak they reached shortly after the company's first drug earned approval this February. Unfortunately, one of ...

It's been a wild roller-coaster ride for Iovance Biotherapeutics (NASDAQ: IOVA). In February, the stock more than doubled in price, then it fell to a 52-week low in July. The stock has since ...

Iovance Biotherapeutics, Inc. announced the grant of inducement stock options for 297,600 shares of common stock to fifty new non-executive employees as part of its Amended and Restated 2021 ...

Iovance Biotherapeutics (IOVA) has appointed Corleen Roche as chief financial officer, effective August 6th, 2025. IOVA -5.97% premarket to $1.89. Source: Press ...